allogeneic NoveCite induced mesenchymal stem cell therapy (NoveCite)

N/A

Report date: 2025/01/26 18:22:23

Base Information

Drug Nameallogeneic NoveCite induced mesenchymal stem cell therapy (NoveCite)
Drug Alias NameNC-iMSCsNC-MSCsallogeneic NoveCite mesenchymal stem cell therapy (Citius Pharmaceuticals)
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Respiratory Distress Syndrome, Adult
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNovellus Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNoveCite Inc
Inactive CompaniesNovellus LtdCitius Pharmaceuticals Inc
Active IndicationsCoronavirus Disease 2019 (COVID-19)Respiratory Distress Syndrome, Adult
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A